Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
Roy S. Herbst, Yi‐Long Wu, Thomas John, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 10, pp. 1830-1840
Open Access | Times Cited: 229

Showing 51-75 of 229 citing articles:

Gene mutation, clinical characteristics and pathology in resectable lung adenocarcinoma
Jian Zou, Wei Han, Yan Hu, et al.
World Journal of Surgical Oncology (2025) Vol. 23, Iss. 1
Open Access
Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study
Marina Chiara Garassino, Yong He, Myung‐Ju Ahn, et al.
Lung Cancer (2025) Vol. 202, pp. 108417-108417
Closed Access
Effect of ground-glass opacity components on the recurrence of pathological stage IB non-small cell lung cancer harboring epidermal growth factor receptor mutations
Yukio Watanabe, Takuo HAYASHI, Aritoshi Hattori, et al.
Surgery Today (2025)
Closed Access
NSCLC: Current Evidence on Its Pathogenesis, Integrated Treatment, and Future Perspectives
Kareem S. Tahayneh, Mayar Idkedek, Firas Abu Akar
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 1025-1025
Open Access
Postoperative radiotherapy for stage pIIIA-N2 non-small cell lung cancer patients undergoing sublobar resection: A retrospective cohort study
Shoufeng Wang, Xin‐Bin Pan, Wei Huang, et al.
Medicine (2025) Vol. 104, Iss. 6, pp. e41462-e41462
Open Access
Immune Checkpoint Inhibitors and Targeted Therapies in Early-Stage Non-Small-Cell Lung Cancer: State-of-the-Art and Future Perspectives
Lucrezia Barcellini, Simone Nardin, G. Sacco, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 652-652
Open Access
Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target
Giannis Mountzios, Stephanie P.L. Saw, Lizza E.L. Hendriks, et al.
Cancer Treatment Reviews (2025) Vol. 134, pp. 102902-102902
Closed Access
Osimertinib in the Treatment of Epidermal Growth Factor Receptor-Mutant Early and Locally Advanced Stages of Non-Small-Cell Lung Cancer: Current Evidence and Future Perspectives
Antonello Veccia, Mariachiara Dipasquale, M. Lorenzi, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 668-668
Open Access
Perioperative Treatment in EGFR‐Mutant Early‐Stage Non‐Small Cell Lung Cancer: Current Evidence and Future Perspectives
Xiaobei Guo, Xiaoyan Liu, Chao Guo, et al.
Thoracic Cancer (2025) Vol. 16, Iss. 4
Open Access
Stage-dependent spatial distribution and prognostic value of CD8+ tissue-resident memory T cells in NSCLC
Liying Yang, Hao Yang, Miaoqing Zhao, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
Real-World Data on Osimertinib-Associated Cardiac Toxicity
Abed Agbarya, Ari Raphael, Hadas Sorotsky, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 5, pp. 1754-1754
Open Access
Longitudinal Analysis of Recurrence and Risk Factors of Early-stage Resected Adenocarcinoma with Common EGFR Mutations: A Multicenter Retrospective Cohort Study in South Korea
June Hong Ahn, Sun Ha Choi, Sun Hyo Park, et al.
Clinical Lung Cancer (2025)
Closed Access
Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma
Masahiro Torasawa, Tatsuya Yoshida, Kouya Shiraishi, et al.
Lung Cancer (2025) Vol. 202, pp. 108494-108494
Closed Access
NNMT promotes acquired EGFR-TKI resistance by forming EGR1 and lactate-mediated double positive feedback loops in non-small cell lung cancer
Jiali Dai, Xiyi Lu, Chang Zhang, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Evaluating the prognostic impact of EGFR mutation on adjuvant chemotherapy efficacy in grade 3 stage IB lung adenocarcinoma
Zhao An, Ning Ye, Jie Mei, et al.
Lung Cancer (2025), pp. 108507-108507
Closed Access
Recent advances in therapeutic strategies for non-small cell lung cancer
Po‐Lan Su, Naoki Furuya, Atif Asrar, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access
Caractérisation moléculaire des cancers du poumon : mise au point et recommandations
Simon Garinet, Audrey Mansuet‐Lupo, Diane Damotte, et al.
Bulletin du Cancer (2025) Vol. 112, Iss. 3, pp. 3S16-3S23
Closed Access
Predictive models of epidermal growth factor receptor mutation in lung adenocarcinoma using PET/CT‐based radiomics features
Zhikang Deng, Di Jin, Pei Huang, et al.
Medical Physics (2025)
Closed Access
Updates on the treatment of epidermal growth factor receptor‐mutant non–small cell lung cancer
Jinyong Kim, Sehhoon Park, Bo Mi Ku, et al.
Cancer (2025) Vol. 131, Iss. S1
Closed Access
Comprehensive insights into systemic therapy for the whole-course management of hepatocellular carcinoma
Jiayun Jiang, Kai Feng, Leida Zhang, et al.
Oncology and Translational Medicine (2025)
Open Access
Molecular characterization of early-stage lung adenocarcinoma presenting as subsolid nodules in a real-life European cohort
Riccardo Tajè, Filippo Tommaso Gallina, M Caterino, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Clinical practice guidelines for perioperative multimodality treatment of non-small cell lung cancer
Wenjie Jiao, Liang Zhao, Jiandong Mei, et al.
Chinese Medical Journal (2025)
Open Access
Real‐World Treatment Patterns and Associated Outcomes in Patients With Resectable Early‐Stage Non‐Small Cell Lung Cancer: The THASSOS International Study
Kumar Prabhash, R. Moor, Tuncay Göksel, et al.
Thoracic Cancer (2025) Vol. 16, Iss. 8
Open Access
Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
Navneet Singh, Megan E. Daly, Nofisat Ismaila, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 27, pp. 4430-4432
Open Access | Times Cited: 10
TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection
Ross A. Soo, Filippo de Marinis, Ji‐Youn Han, et al.
Clinical Lung Cancer (2023) Vol. 25, Iss. 1, pp. 80-84
Open Access | Times Cited: 10

Scroll to top